|
Experimental Genetics Group
Neurobiol Dis. 2009 Aug;35(2):193-200. Dewachter I1, Ris L2, Jaworski T1, Seymour CM1, Kremer A1, Borghgraef P1, De Vijver H1, Godaux E2, Van Leuven F1*. 1Experimental Genetics Group, Department of Human Genetics, K.U.Leuven, Leuven, Belgium. 2Laboratory of Neurosciences, University of Mons-Hainaut, Mons, Belgium. *Corresponding author. Accumulating evidence implicates deregulation of GSK3ss as a converging pathological event in Alzheimer's disease and in neuropsychiatric disorders, including bipolar disorder and schizophrenia. Although these neurological disorders share cognitive dysfunction as a hallmark, the role of GSK3ss in learning and memory remains to be explored in depth. We here report increased phosphorylation of GSK3ss at Serine-9 following cognitive training in two different hippocampus dependent cognitive tasks, i.e. inhibitory avoidance and novel object recognition task. Conversely, transgenic mice expressing the phosphorylation defective mutant GSK3ss[S9A] show impaired memory in these tasks. Furthermore, GSK3ss[S9A] mice displayed impaired hippocampal L-LTP and facilitated LTD. Application of actinomycin, but not anisomycin, mimicked GSK3ss[S9A] induced defects in L-LTP, suggesting that transcriptional activation is affected. This was further supported by decreased expression of the immediate early gene c-Fos, a target gene of CREB. The combined data demonstrate a role for GSK3ss in long term memory formation, by inhibitory phosphorylation at Serine-9. The findings are fundamentally important and relevant in the search for therapeutic strategies in neurological disorders associated with cognitive impairment and deregulated GSK3ss signaling, including AD, bipolar disorder and schizophrenia. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
Copyright © Katholieke Universiteit Leuven | Comments on the content: Fred Van Leuven Production:Annick Vogels| Most recent update: October 21, 2009 | Disclaimer URL: http://med.kuleuven.be/legtegg/ |